{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:17:56Z","timestamp":1773825476129,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jvir.2018.03.016","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T19:40:29Z","timestamp":1529091629000},"page":"1078-1084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A\u00a0VX2 Tumor Model Study"],"prefix":"10.1016","volume":"29","author":[{"given":"In Joon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myungsu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Yun","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-6872","authenticated-orcid":false,"given":"Jin Wook","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2018.03.016_bib1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2018.03.016_bib2","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2018.03.016_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2018.03.016_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000371522","article-title":"Single-agent versus combination doxorubicin-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a single-blind, randomized, phase II trial","volume":"89","author":"Liu","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.jvir.2018.03.016_bib6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jvir.2016.01.135","article-title":"Single- versus triple-drug chemoembolization for hepatocellular carcinoma: comparing outcomes by toxicity, imaging response, and survival","volume":"27","author":"Mouli","year":"2016","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/djs464","article-title":"Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial","volume":"105","author":"Shi","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jvir.2018.03.016_bib8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CAD.0000000000000371","article-title":"Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"27","author":"Zhao","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jvir.2018.03.016_bib9","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00270-012-0352-x","article-title":"Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma","volume":"35","author":"Sahara","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib10","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2174\/138945011798829366","article-title":"Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic","volume":"12","author":"Spear","year":"2011","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jvir.2018.03.016_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.24975","article-title":"Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer","volume":"116","author":"McKeage","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2018.03.016_bib12","first-page":"189","article-title":"Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate","volume":"19","author":"Chaplin","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jvir.2018.03.016_bib13","first-page":"1829","article-title":"Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature","volume":"57","author":"Dark","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.jvir.2018.03.016_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3348\/kjr.2012.13.2.195","article-title":"Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intraarterial versus intravenous administration","volume":"13","author":"Seong","year":"2012","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib15","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1021\/jm1002414","article-title":"Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors","volume":"53","author":"Lee","year":"2010","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jvir.2018.03.016_bib16","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1016\/j.bmcl.2010.05.060","article-title":"Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog","volume":"20","author":"Lee","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jvir.2018.03.016_bib17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s10637-012-9915-6","article-title":"Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI","volume":"31","author":"Kim","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jvir.2018.03.016_bib18","first-page":"1715","article-title":"Enhanced efficacy of CKD-516 in combination with doxorubicin: pre-clinical evaluation using a hepatocellular carcinoma xenograft model","volume":"34","author":"Kim","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jvir.2018.03.016_bib19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s10637-013-0043-8","article-title":"CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model","volume":"32","author":"Moon","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jvir.2018.03.016_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1148\/radiol.14131165","article-title":"Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors","volume":"272","author":"Joo","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2018.03.016_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14366\/usg.13006","article-title":"Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors","volume":"33","author":"Joo","year":"2014","journal-title":"Ultrasonography"},{"key":"10.1016\/j.jvir.2018.03.016_bib22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3348\/kjr.2015.16.5.1029","article-title":"Dynamic contrast-enhanced MRI using a macromolecular MR contrast agent (P792): evaluation of antivascular drug effect in a rabbit VX2 liver tumor model","volume":"16","author":"Park","year":"2015","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4143\/crt.2014.258","article-title":"Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors","volume":"48","author":"Oh","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jvir.2018.03.016_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1148\/radiol.2015141974","article-title":"Monitoring vascular disrupting therapy in a rabbit liver tumor model: relationship between tumor perfusion parameters at IVIM diffusion-weighted MR imaging and those at dynamic contrast-enhanced MR imaging","volume":"278","author":"Joo","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2018.03.016_bib25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/RLI.0b013e31829c13ef","article-title":"Improved drug targeting to liver tumors after intra-arterial delivery using superparamagnetic iron oxide and iodized oil: preclinical study in a rabbit model","volume":"48","author":"Lee","year":"2013","journal-title":"Invest Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib26","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.acra.2009.09.009","article-title":"Dynamic evolutionary changes in blood flow measured by MDCT in a hepatic VX2 tumor implant over an extended 28-day growth period: time-density curve analysis","volume":"16","author":"Wu","year":"2009","journal-title":"Acad Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib27","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jvir.2010.11.035","article-title":"Comparison between transauricular and transfemoral arterial access for hepatic artery angiography in a rabbit model","volume":"22","author":"Chang","year":"2011","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib28","series-title":"R: A language and environment for statistical computing","year":"2017"},{"key":"10.1016\/j.jvir.2018.03.016_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jemt.10250","article-title":"Microfilaments and microtubules maintain endothelial integrity","volume":"60","author":"Lee","year":"2003","journal-title":"Microsc Res Tech"},{"key":"10.1016\/j.jvir.2018.03.016_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4329\/wjr.v3.i1.1","article-title":"Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer","volume":"3","author":"Wang","year":"2011","journal-title":"World J Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/RLI.0b013e31818e5ace","article-title":"Treatment of rodent liver tumor with combretastatin A4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology","volume":"44","author":"Wang","year":"2009","journal-title":"Invest Radiol"},{"key":"10.1016\/j.jvir.2018.03.016_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s002800050611","article-title":"Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid","volume":"39","author":"Pruijn","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jvir.2018.03.016_bib33","first-page":"157","article-title":"Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma","volume":"8","author":"Nelkin","year":"2001","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jvir.2018.03.016_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18388\/abp.2009_2528","article-title":"Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors","volume":"56","author":"Mitrus","year":"2009","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.jvir.2018.03.016_bib35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0959-8049(05)80063-2","article-title":"Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol","volume":"28","author":"Konno","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvir.2018.03.016_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1148\/radiol.2291021029","article-title":"Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor","volume":"229","author":"Yoon","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2018.03.016_bib37","first-page":"2983","article-title":"Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma","volume":"31","author":"Okabe","year":"2011","journal-title":"Anticancer Res"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044318310455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044318310455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T06:02:47Z","timestamp":1760940167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044318310455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1051044318310455"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2018.03.016","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A\u00a0VX2 Tumor Model Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2018.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2018","name":"copyright","label":"Copyright"}]}}